• Advaxis Inc., of Princeton, N.J., said it entered a memorandum of understanding with FusionVax Inc., of Taiwan, under which Advaxis will, subject to a definitive agreement, exclusively license its lead clinical-stage product candidate, ADXS-HPV, to FusionVax for development in Asia.